ReviewClinical journal of the American Society of Nephrology : CJASN2026
Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Eculizumab for rapidly progressive glomerulonephritis in children.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Advances in therapy · 2026Article
- Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?European journal of immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pharmacologic complement inhibition offers a promising therapeutic strategy for several complement-mediated kidney diseases. Yet, at present, nephrologists must rely on an incomplete toolkit of histopathologic and circulating biomarkers to assess complement activity in complement-mediated kidney diseases. Our clinical capacity to characterize and monitor pathologically dysregulated complement for disease prognosis, to inform patient selection, and to evaluate therapeutic efficacy severely lags behind the growing number of complement inhibitors under development. Reliable, sensitive complement biomarkers that are suitable for clinical assessment are needed for the timely and optimal implementation of existing and upcoming therapeutics. Despite this urgent need and growing research efforts, the repertoire of clinically available complement biomarker assays has proven refractory to expansion. This is, in part, due to a myriad of practical challenges limiting the information reliably interpreted from existing complement biomarkers and hindering the translation of novel biomarkers from research settings into the clinical pathology laboratory. In this article, the authors review commonly evaluated complement biomarkers within the context of an evolving therapeutic landscape, as well as the practical challenges related to their effective application. Noteworthy, emerging biomarkers are also discussed, along with the challenges in translating robust markers of complement activity from research settings into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.